Interval cancer rates are a major determinant of the success of a screening programme. In the Swedish two county study, on which the United Kingdom programme is based, a 39% reduction in mortality was observed in screened women aged 50-64. Using data from the Swedish study, the relationship between interval cancer incidence and the likely future effect on breast cancer mortality was quantified. In East Anglia, as elsewhere in the United Kingdom, interval cancers rates are nearly double those obtained in Sweden: interval cancer rates in the first, second, and third years respectively, after a negative screen were 24%, 59%, and 79% ofthe expected underlying incidence in the absence of screening. The corresponding figures from the two county study were 17%, 30%, and 56%. From these it was estimated that the mortality reduction in East Anglia will be 21%, which is lower than the 35% observed in invited women in this age group in the Swedish two county study and the 25% specified in the Health of the Nation target. In a rereading exercise, using screening mammograms from women who were screen normal, who had screen detected cancers, or who subsequently developed interval cancers, four out of five radiologists recommended recall for around 70% of the original mammograms (classed as screen normal at time of screening) from 33 interval cancers. This suggests that sensitivity is a contributory factor to the higher interval cancer rates in East Anglia.
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The National Health Service breast screening programme (NHSBSP) was implemented after publication of the Forrest report, 1 which advocated screening of women aged 50-64, every three years, by single view mammography. This protocol, and the targets set for the NHSBSP, were based on the design and results of the Swedish two county study, which achieved a 35% mortality reduction in women invited to screening aged 50--64. 2 In a screening programme, cancers may arise in one of three different categories: those cancers that are detected by screening; those that arise in women who refuse the screening invitation; and those that present symptomatically in women who were screened negative, before the next screening appointment is due. Cancers in this latter category are termed interval cancers.
Interval cancers are of prime importance to the success of a screening programme because the relative proportions and prognostic characteristics of interval and screen detected cancers will determine the long term mortality reduction achieved by screening.r" Thus the success of the Swedish two county study in terms of mortality reduction is attributable not only to the large number of cancers detected at screening, but also to the low rates of interval cancers arising between screens.
Early results showing that national targets for compliance and cancer detection rates at first screen were being achieved" suggested that the NHSBSP was on course for meeting the Health of the Nation objective of a 25% reduction in breast cancer mortality in women of screening age by the year 2000. 7 However, recently published information on rates of interval cancers for the North Western region show these to be well in excess of target." Our own findings in East Anglia suggest that this is not an isolated problem. Here we report the interval cancer rates seen in the East Anglian programme and estimate the associated screening induced reduction in mortality we may subsequently hope to achieve in the region. We also describe the results of a rereading exercise designed to investigate possible factors affecting these interval cancer rates.
Finally, we explore the apparent paradox that high rates of interval cancers were observed in East Anglia, despite meeting United Kingdom national targets for the cancer detection rate at the prevalence screen."
Subjects and methods
We compared interval cancer rates observed in East Anglia with those obtained in the Swedish two county study. This comparison allows estimation of the likely mortality rate reduction that will occur as a result of screening in East Anglia.
In East Anglia the screening programme has been monitored since its inception. Efforts have been made to identify and record all cases of interval cancers. Identification of interval cancers is by computer matching files ofwomen screened (obtained from the region's screening units) with those of women registered with breast cancer at the East Anglian Cancer Registry, which operates a policy of "fast tracking" all breast cancer registrations. Matching is by surname, forenames, and date of birth, using a custom written matching programme incorporating a version of Soundex. 10 Validity of matches is confirmed by manual checking of address details. Interval cancer status is attributed only to those cases in which breast cancer is diagnosed within three years of a negative screen. Further cases are obtained directly from the screening units: generally these are either too recent to be registered by the cancer registry, or have occurred in women who had moved out of the region after screening.
For the purposes of this study, only cases of invasive cancer have been included: interval cases of carcinoma in situ form less than 4% of all interval cancer cases in the East Anglian programme and have not been considered in this analysis. The data presented here comprise all relevant registrations in the East Anglian Cancer Registry to 20 December 1994, and those notified directly by the screening offices, which cover virtually all diagnoses to 20 December 1993 (that is, allowing one full year to complete the registration process). Annual interval cancer rates after a negative screen are calculated by dividing the total number of interval cancers arising in a given 12 month period by the total number of women screened before that period. The denominator (the total number of women screened) is not adjusted for migration or death. Interval cancer rates are also expressed as proportionate incidences -that is, as percentages of the incidence that would have occurred in the absence of screening. Calculation of proportionate incidence rates requires knowledge of the incidence that would have been observed in this population, by age, in the absence of screening. This was estimated by linear extrapolation of the rates for invasive cancer observed by the East Anglian Cancer Registry in the years 1976-1988, which gave values for the age groups 50-54, 55-59, and 60-64 of 20, 21, and 24 cancers per 10 4 person years respectively, as average rates over the period 1990-1993. The invasive incidence rate in the entire age group 50-64 over the same period was 22 cancers per 10 4 person years. Expression of interval cancer rates as proportionate incidences allows comparison of results between programmes that have different prescreening incidence rates. 181 We also investigated the strategy adopted at screening for recalling women for further assessment. This was done by means of a mammogram rereading exercise. Three readers trained in Sweden (one from Sweden, one from the United Kingdom outside East Anglia, and one from New York) and two East Anglian screening radiologists reread 106 sets of East Anglian screening mammograms. These mammograms were predominantly from the initial prevalence screen, and were randomly selected from East Anglia's initial six breast screening units. Of these, one third (36) were from women who had not been diagnosed with breast cancer, were not recalled for assessment, and who have not developed an interval cancer (screen normals); one third (37) had been recalled and histologically diagnosed with a cancer that measured 1 cm or less as a result of the screen (screen detected); and one third (33) had been classed as screen normal but subsequently developed an invasive interval cancer within three years of their negative screen (interval). The mammograms were read independently and the readers were blind to the category (screen detected/interval/screen normal) but knew that it was a rereading exercise focusing on interval cancers. Two mammographic views were available for most examinations, and the same views were read by all readers. For the interval cancers, subsequent diagnostic mammograms were not made available to the readers for correlation with the original screening mammograms. Thus it was not possible to correlate the position of any suspicious lesions on a screening mammogram with the actual position ofthe interval cancer on a diagnostic mammogram. Each reader classed the mammograms as either non-recall (that is, normal), recall for further examinations owing to suspicion of abnormality, or technical recall. Classification as technical recall implied that either image quality was too poor to allow reading or that the quality was insufficient to permit a decision to be made on a possibly suspicious abnormality.
Results
In the Swedish two county study the reduction in breast cancer mortality among women invited to screening aged 50-64 was 35%.2 This can be translated to a 39% reduction in women attending for screening." Assuming, as in the two county study, that patients with interval cancer have similar survival to patients with cancer in the control group, one can calculate the effect on breast cancer mortality of different rates of interval cancers (see Appendix). This prediction ofmortality effect by detection status has been shown to be effective in the two county study," Table 1 gives such estimates both for screened women and for populations with 70% and 80% compliance. It has been assumed that the non-compliers have a higher (relative mortality 1,25) breast cancer mortality than the control group, a general finding in studies in Europe. 5 12 13 • The combined proportionate incidence is the proportion of incident cancers arising as interval cancers in the interscreening period. For a three year interscreening period it is calculated by dividing the sum of the annual interval cancer proportionate incidences (that is, the annual interval cancer rates expressed as a percentage of the underlying incidence rate) in the three years after a negative screen by three. • Insufficient time has elapsed since screening of women aged 50 and 51 for accurate evaluation of interval cancer rates.
t Proportionate incidence is calculated by dividing the interval cancer rate by the underlying incidence rate in the absence of screening (which is 2·2 cancers per 10' women screened, in East Anglia).
• Laszlo Tabar, personal communication. ' \I Size data available for 89% of cancers.
NIA=not applicable.
will be similar to that in women aged 50-64; also that the interval cancer rates observed in women aged 52-54 would apply for women aged 50 and 51.
In East Anglia the sum of the proportionate incidences in the three year interscreening interval is 1·62 (that is, 0·24 + 0·59 + 0'79, with 95% confidence interval 1'34--1'91). Thus over three years just over half of the expected incidence occurred as interval cancers (that is, 1·62...;-3 = 0,54). In the Swedish two county study the proportionate interval cancer incidence rates (with 95% confidence intervals) for women aged 50-64 (as calculated by weighted average of the rates for 50-59 and 60-69 5 ) and with a 33 month interscreening interval were 0'17 (0'12-0'24), 0·30 (0'23-0'38) and 0·53 (0'41--0'68) in the periods 0-12, 13-24, and 25-33 months after a negative screen." Thus in the Swedish programme the proportion of incident cancers arising as intervals was approximately 34%, (that is, (17% +30% + 56%) ...;-3 = 34%, having adjusted the 25-33 month interval cancer proportionate incidence to give a projected figure for the period 24--36 months following a negative screen). Comparison of table 2 with the Swedish two county figures shows that in the first two years after screening the East Anglian interval cancer rates are nearly twice the target. For year 3 there is some uncertainty as the two county figures have been extrapolated to give a projected figure for the full third year. The East Anglian rates, however, are clearly considerably higher. The rates in table 2 suggest that with a 54% proportion of interval cancers among the incident cases and the 80% compliance rate obtained in East Anglia the consequent effect will be to diminish the screening induced reduction in breast cancer mortality to 21 %, as indicated in table 1.
Further analysis of data from the Swedish two county trial for the age group 50-64 (Tabar L, personal communication) has allowed more direct comparison of the performance of the East Anglian and two county programmes. Table 3 compares the cancer detection rates in the East Anglian and two county programmes for all invasive cancers and for small ( :::;; 10 mm) invasive cancers. The rates are given both per thousand women screened and as a multiple of the underlying incidence rate. Table 4 gives the results of the rereading exercise, by reader. Interestingly, readers 1, 2, 3, and 5 had strikingly similar rates of recommendation for recall (with reader 2 ex- showing the numbers of interval cancers, the population from which they arose, and their incidence rates and proportionate incidence rates. All interval cancers arising within three years of a negative screen in women invited as part of the normal call/recall system have been included. Rates are presented for the age group 52-64 at screening only because, in the East Anglian programme, women are invited by five year birth cohort and women aged 50 and 51 were not screened until the fourth year of the programme. Thus insufficient time has elapsed to allow accurate estimation of interval cancer rates in these women. As the underlying incidence rate in women aged 50-54 is only slightly less than that in women aged 55-59, assumptions have been made that the underlying incidence rate in women aged 52-64 hibiting a higher tendency to technical recall). Reader 4, clearly distinct in recall rates, had nevertheless similar discriminating power (reader 1 recalled all the screen detected cancers, reader 4 did not recall any of the screen normals). Table 5 summarises the agreement among the readers, and gives the number recommending recall by category of mammogram.
Discussion
In the United Kingdom, the Health of the Nation target for breast screening is a 25% reduction in breast cancer mortality in women aged 50-69 who have been invited for screening, by the year 2000. 7 • In this paper we have shown the importance of the rate of interval cancers in determining the impact of breast screening on future breast cancer mortality rates. The crucial variable is the proportion of incident cancers that present clinically as interval cancers rather than being detected at screening. The results from the initial years of the East Anglian programme demonstrate a rate of interval cancers that appears incompatible with a future mortality reduction of 25%. One would predict a reduction in the order of 21 %, based on the observed interval cancer rates and compliance rates for the region (see table 1), this reduction falling to 18 % with a lower compliance rate of 70% (the national target figure) .
In some screening programmes patients with interval cancer have worse survival than patients with cancer arising in an unscreened population." Under these circumstances the contribution ofinterval cancers to breast cancer mortality will be even larger. It is also possible, of course, that patients with interval cancers may have better survival than those with cancers arising in an unscreened population owing to increased awareness of breast disease. However, the prognostic characteristics of cancers arising as intervals in the East Anglian programme do not appear different from those of cancers arising symptomatically in unscreened women, thus it is reasonable to assume similar survival rates in the two groups (McCann J, unpublished observations). The observed rate for interval cancers appears to result from a first screen detection rate for small cancers that is low compared with the two county study. The detection rate of small cancers in East Anglia is 58% of that expected from the two county results when the results are adjusted for differences in the underlying incidence rates. This deficit of 1·1 cancers per thousand women (that is, 2,6-1'5; table 3) equates approximately with the excess of interval cancers seen in East Anglia in the three years after a negative screen (that is, ((0'24+0'59+0'79)-(0'17+0'30+ 0'56))2,2). For larger cancers (>10mm) the detection rates as a multiple of the underlying incidence rate are roughly the same in the two programmes (1,7 in East Anglia compared with 1·6 in the two county study). It is interesting to note that the United Kingdom national target for cancer detection rate at the prevalent screen was set at five cancers per thousand women, including in situ cancers." This figure is to be compared with the rate for invasive cancers of 6·2 per thousand women that the East Anglian programme should have achieved to parallel the two county results. The national targets are currently under revision. As the benefit of screening derives mainly from the good prognosis of small screen detected cancers," the long term mortality reduction may undergo further diminution.
The results of the rereading exercise suggest that a considerable proportion of the interval cancers might have been detected at screening. Four out of five radiologists recommended recall or technical recall for between 70% and 76% of the screening mammograms for the interval cancer cases. This suggests that recall policy (and not necessarily discriminating power) of individual radiologists may account, at least in part, for differing interval cancer rates. From table 4 it is clear that although four of the readers individually recommended recall for 73% of the interval cancers, this was at the expense of recommending recall for some 30% of the screen normals. Clearly this situation would lead to unacceptably high recall rates in the normal screening situation. Table  5 suggests that better discrimination is obtained by more readers: with two or more readers simultaneously recommending recall, 85% of interval cancers would have been recalled, but also 36% ofscreen normals (although no screen detected cancers would have been missed); with three or more readers simultaneously recommending recall, 70% of interval cancers would have been recalled and 14% of screen normals (and only one screen detected cancer missed); with four or more readers simultaneously recommending recall, 48% of interval cancers would be recalled and only one (3%) screen normal (however, four screen detected cancers would have been missed).
It should be emphasised that there is no immediate prescriptive implication of the results from the rereading exercise. Clearly in practice, at best, double reading will be available. Nevertheless, these results indicate the potential for the recall at the screening stage of more than 50% of women who subsequently develop an interval cancer. If it is assumed that recall for assessment always results in detection of any malignancy present, this would almost halve the interval cancer rates. However, in the rereading exercise no attempt was made to compare the position of the suspicious lesions on the interval cancer screening mammograms with the actual position of the tumours on symptomatic mammograms. Thus it may be that a decision to recall made upon rereading would not automatically have led to the diagnosis of cancer and hence prevented later symptomatic presentation as an interval cancer. In this context the procedures at assessment may be of importance.
The overall results presented display a certain coherence. Compared with the Swedish two county study, the East Anglian programme has observed a greater number of interval cancers and a smaller number of screen detected cancers, specifically small (:5:10 mm) cancers. In quantitative terms the excess of interval cancers is roughly balanced by the deficit in small screen detected cancers. This suggestion of lower sensitivity in the East Anglian programme is consistent with the results of the rereading exercise in which, under test conditions, many of the interval cancers that were originally deemed normal at screening were then selected for recall. Further investigation is currently underway to classify all of the region's interval cancers into one of the four categories true interval/radiographically occult/false negative/ unclassifiable. Thus, by quantifying the number of false negatives in a large series of interval cancers, we may determine our scope for reducing interval cancer rates by improving screening sensitivity.
Three approaches might be taken to changing the interval:incident cancer ratio to a level at which one would predict a reduction in breast cancer mortality closer to 25%. Firstly, one can reduce the interscreen interval to two years, as previously advocated." The interval: incident cancer ratio (on the basis of table 2) would then be about 40% (that is, (0'24 +0'59) --;-2), clearly mere favourable as indicated by table 1. Disadvantages to this approach are the costs, which would be high, and the current national shortage of radiologists willing to participate in the screening programme." Furthermore, this approach does not address the issue of why interval cancer rates are high, and clearly will not affect interval cancer rates in the first two years after a negative screen. Secondly, one can wait in the hope that improvements will occur spontaneously with experience -a low cost approach often favoured in the health service. However, it has not always been the experience in other programmes that interval cancer rates decrease in the second screening round," and it will require several further years of monitoring before significant interval cancer data for the second screening round will be available for analysis. The third option would be to explore the possibility of changing screening practice to reduce the interval:incident cancer ratio without an unacceptable increase in recalls for assessment. Maximising compliance rates will clearly be important." However, the goal must be to improve screening practice such that high specificity (low unnecessary recall rate) and high sensitivity (high detection rate) can be achieved with only two readers. The next step is to determine whether practicable measures can be identified that are both feasible and acceptable. Several avenues of analysis are currently under investigation, both regionally and nationally, and will be the subject of a future publication.
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Appendix: Calculation of the predicted reduction in mortality for different interval cancer proportionate incidences In the Swedish two county study a 39% reduction in breast cancer mortality was achieved in screened women aged 50-64 with a 34% proportion of incident cancers arising as intervals in the interscreening period (that is, 34% combined proportionate incidence). This reduction in mortality occurred throughout the entire screened population, whose cancers were either screen detected or arose as intervals.
If we assume that the mortality rate among interval cancer cases is the same as that in unscreened women, then the mortality reduction must occur only in the cases of screen detected cancers. Of the cancers expected to arise in the three year interscreening interval, 34% were intervals, leaving 100 -34% = 66% as screen detected cancers. To calculate the mortality reduction associated with screen detected cancers: Let x be the mortality rate amongst screen detected cancers 0'66x+ (0'34 x 0) = 0·39 x= 0·39 -i-0·66 = 0'59
Thus there is a 59% reduction in mortality associated with screen detected cancers. The relative mortality associated with screen detected cancers is therefore 100% -59% =41 %.
With 100% compliance If the combined proportionate incidence is increased to 40% then the proportion of screen detected cancers amongst incidence cases will be reduced to 60% (that is, 100% -40%). The reduction in mortality will be 60% of 59% = 35%.
With less than 100% compliance
In a population with less than 100% compliance it is necessary to allow for the noncompliers who have an increased risk of dying from breast cancer (relative mortality of 1·25 compared with the compliers). However, in an unscreened group there would have been a similar level of non-compliance had they been invited for screening. Because, in an unscreened group there will be no overall mortality reduction, the increased relative mortality associated with the would-be refusers must be compensated for by a decreased relative mortality in the would-be acceptors. To determine mortality reductions associated with different rates of combined interval cancer proportionate incidences, actual relative mortality rates must be calculated for screen detected and interval cancers. For each level of compliance it is necessary to calculate adjustment factors to take into account the decreased relative mortality associated with complying with the invitation to screening.
With 70% compliance 0'7xi+ 0·3 x 1·25 = 1 xi = ((1 -(0,3 x 1,25) ) -i-0,7) = 0·89 where xi is the adjustment factor associated with 70% compliance to be applied to the figures previously determined for relative mortality amongst compliers (screen detected and interval cancers). 185 With a combined proportionate interval cancer incidence of 34%, the proportion of screen detected cancers amongst incidence cases will be 66% (that is, 100%-34%). With relative mortalities of 1·25 in the refusers, 0·41 for screen detected cancers and 1·00 for interval cancers, and with an adjustment factor of 0·89 for compliers in a population with 70% compliance, the relative mortality will be 0·7 x ((0'66 x 0'41 x 0'89) + (0'34 x 1 x 0'89)) + 0·3 x 1·25 = 0·76. This is equivalent to a 24% (100 -76%) reduction in mortality.
With 80% compliance
The adjustment factor xi to be applied to relative mortality rates for screen detected cancers and interval cancers becomes 0·8 xxi+0'2 x 1·25 = 1 xi = ((1 -(0'2 x 1,25) ) -i-0'8) = 0'94.
